Arsenic Trioxide
(NFHSKYFEYBYPAB-UHFFFAOYSA-N)
Structure
- SMILES
- [O-2].[O-2].[O-2].[AsH3+3].[AsH3+3]
- Molecular Formula:
- As2H6O3
- Molecular Weight:
- 203.889
- Log P:
- -0.4430
- Hydrogen Bond Acceptor:
- 0
- Hydrogen Bond Donor:
- 2
- TPSA:
- 0
- CAS Number(s):
- N/A
Synonym(s)
1.
Arsenic Trioxide
2.
Arsenic Oxide (As2O3)
3.
Arsenic Oxide (As4O6)
4.
Arsenic(III) Oxide
5.
Arsenolite
6.
Arsenous Anhydride
7.
As2O3
8.
As4O6
9.
Diarsenic Trioxide
10.
Naonobin
11.
Tetra-Arsenic Hexaoxide
12.
Tetra-Arsenic Oxide
13.
Tetraarsenic Hexaoxide
14.
Tetraarsenic Oxide
15.
Trisenox
16.
Trixenox
17.
Tetra Arsenic Hexaoxide
18.
Tetra Arsenic Oxide
External Link(s)
| MeSH | D000077237 |
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | White blood cell count decreased | FAERS: 26 | US FAERS | |
| 2 | Alanine Aminotransferase Increased | FAERS: 24 | US FAERS | |
| 3 | Pancytopenia | FAERS: 20 | US FAERS | |
| 4 | Aspartate Aminotransferase Increased | FAERS: 16 | US FAERS | |
| 5 | Febrile Neutropenia | FAERS: 14 | US FAERS | |
| 6 | Neutropenia | FAERS: 14 | US FAERS | |
| 7 | Pneumonia | FAERS: 11 | US FAERS | |
| 8 | Pericardial effusion | FAERS: 10 | US FAERS | |
| 9 | Disseminated Intravascular Coagulation | FAERS: 9 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 10 | Gamma-Glutamyltransferase Increased | FAERS: 9 | US FAERS | |
| 11 | Leukocytosis | FAERS: 8 | US FAERS | |
| 12 | Myocardial Infarction | FAERS: 8 | US FAERS | |
| 13 | Nausea | FAERS: 8 | US FAERS | |
| 14 | Retinoic acid syndrome | FAERS: 7 | US FAERS | |
| 15 | Vomiting | FAERS: 7 | US FAERS | |
| 16 | Acute promyelocytic leukaemia differentiation syndrome | FAERS: 6 | US FAERS | |
| 17 | Atrial Fibrillation | FAERS: 6 | US FAERS | |
| 18 | Chest Pain | FAERS: 6 | US FAERS | |
| 19 | Hypotension | FAERS: 6 | US FAERS | |
| 20 | Hypoxia | FAERS: 6 | US FAERS | |
| 21 | Leukopenia | FAERS: 6 | US FAERS | |
| 22 | Septic Shock | FAERS: 6 | US FAERS | |
| 23 | Abdominal Pain | FAERS: 5 | US FAERS | |
| 24 | Blood alkaline phosphatase increased | FAERS: 5 | US FAERS | |
| 25 | Disease Progression | FAERS: 5 | US FAERS | |
| 26 | Dizziness | FAERS: 5 | US FAERS | |
| 27 | Headache | FAERS: 5 | US FAERS | |
| 28 | Infection | FAERS: 5 | US FAERS | |
| 29 | Sepsis | FAERS: 5 | US FAERS | |
| 30 | Blood lactate dehydrogenase increased | FAERS: 4 | US FAERS | |
| 31 | Dehydration | FAERS: 4 | US FAERS | |
| 32 | Malignant neoplasm progression | FAERS: 4 | US FAERS | |
| 33 | Pulmonary Embolism | FAERS: 4 | US FAERS | |
| 34 | Accidental exposure to product | FAERS: 3 | US FAERS | |
| 35 | Altered state of consciousness | FAERS: 3 | US FAERS | |
| 36 | Blood creatine phosphokinase increased | FAERS: 3 | US FAERS | |
| 37 | Blood creatinine increased | FAERS: 3 | US FAERS | |
| 38 | Blood potassium decreased | FAERS: 3 | US FAERS | |
| 39 | Cytolytic hepatitis | FAERS: 3 | US FAERS | |
| 40 | Disorientation | FAERS: 3 | US FAERS | |
| 41 | Drug ineffective | FAERS: 3 | US FAERS | |
| 42 | Extravasation | FAERS: 3 | US FAERS | |
| 43 | Fatigue | FAERS: 3 | US FAERS | |
| 44 | Fluid overload | FAERS: 3 | US FAERS | |
| 45 | MYELODYSPLASTIC SYNDROME | FAERS: 3 | US FAERS | |
| 46 | Myalgia | FAERS: 3 | US FAERS | |
| 47 | Neutrophil count decreased | FAERS: 3 | US FAERS | |
| 48 | Pericarditis | FAERS: 3 | US FAERS | |
| 49 | Pneumonitis | FAERS: 3 | US FAERS | |
| 50 | Protein total decreased | FAERS: 3 | US FAERS | |
| 51 | Respiratory Failure | FAERS: 3 | US FAERS | |
| 52 | Respiratory distress | FAERS: 3 | US FAERS | |
| 53 | Stem cell transplant | FAERS: 3 | US FAERS | |
| 54 | Sudden death | FAERS: 3 | US FAERS | |
| 55 | Tremor | FAERS: 3 | US FAERS | |
| 56 | nervous system disorder | FAERS: 3 | US FAERS | |
| 57 | Acute respiratory failure | FAERS: 2 | US FAERS | |
| 58 | Anorexia | FAERS: 2 | US FAERS | |
| 59 | Aphasia | FAERS: 2 | US FAERS | |
| 60 | Arthralgia | FAERS: 2 | US FAERS | |
| 61 | Asterixis | FAERS: 2 | US FAERS | |
| 62 | Asthenia | FAERS: 2 | US FAERS | |
| 63 | Atelectasis | FAERS: 2 | US FAERS | |
| 64 | Back Pain | FAERS: 2 | US FAERS | |
| 65 | Blood albumin decreased | FAERS: 2 | US FAERS | |
| 66 | Blood magnesium decreased | FAERS: 2 | US FAERS | |
| 67 | Bone marrow necrosis | FAERS: 2 | US FAERS | |
| 68 | Bone pain | FAERS: 2 | US FAERS | |
| 69 | Bradycardia | FAERS: 2 | US FAERS | |
| 70 | Bronchopneumonia | FAERS: 2 | US FAERS | |
| 71 | Cardiotoxicity | FAERS: 2 | US FAERS | |
| 72 | Catheter related infection | FAERS: 2 | US FAERS | |
| 73 | Cerebral Infarction | FAERS: 2 | US FAERS | |
| 74 | Chills | FAERS: 2 | US FAERS | |
| 75 | Deafness | FAERS: 2 | US FAERS | |
| 76 | Diplopia | FAERS: 2 | US FAERS | |
| 77 | Drug toxicity | FAERS: 2 | US FAERS | |
| 78 | Dry skin | FAERS: 2 | US FAERS | |
| 79 | Dyspnoea exacerbated | FAERS: 2 | US FAERS | |
| 80 | Encephalitis | FAERS: 2 | US FAERS | |
| 81 | Eye irritation | FAERS: 2 | US FAERS | |
| 82 | Febrile bone marrow aplasia | FAERS: 2 | US FAERS | |
| 83 | General physical condition abnormal | FAERS: 2 | US FAERS | |
| 84 | Head titubation | FAERS: 2 | US FAERS | |
| 85 | Hepatotoxicity | FAERS: 2 | US FAERS | |
| 86 | Inflammation | FAERS: 2 | US FAERS | |
| 87 | Lobar Pneumonia | FAERS: 2 | US FAERS | |
| 88 | Metabolic acidosis | FAERS: 2 | US FAERS | |
| 89 | Multiple Myeloma | FAERS: 2 | US FAERS | |
| 90 | Myositis | FAERS: 2 | US FAERS | |
| 91 | Neuropathy | FAERS: 2 | US FAERS | |
| 92 | Neutropenic sepsis | FAERS: 2 | US FAERS | |
| 93 | Oliguria | FAERS: 2 | US FAERS | |
| 94 | Overdose | FAERS: 2 | US FAERS | |
| 95 | Pancreatitis | FAERS: 2 | US FAERS | |
| 96 | Phlebitis | FAERS: 2 | US FAERS | |
| 97 | Pleurisy | FAERS: 2 | US FAERS | |
| 98 | Pneumocystis jiroveci pneumonia | FAERS: 2 | US FAERS | |
| 99 | Product use issue | FAERS: 2 | US FAERS | |
| 100 | Pruritus | FAERS: 2 | US FAERS | |
| 101 | Pulmonary toxicity | FAERS: 2 | US FAERS | |
| 102 | Sinus bradycardia | FAERS: 2 | US FAERS | |
| 103 | Sinusitis | FAERS: 2 | US FAERS | |
| 104 | Somnolence | FAERS: 2 | US FAERS | |
| 105 | Supraventricular tachycardia | FAERS: 2 | US FAERS | |
| 106 | Tachycardia | FAERS: 2 | US FAERS | |
| 107 | Thrombocytopenia | FAERS: 2 | US FAERS | |
| 108 | Transaminases increased | FAERS: 2 | US FAERS | |
| 109 | Vasculitis | FAERS: 2 | US FAERS | |
| 110 | Accidental exposure | FAERS: 1 | US FAERS | |
| 111 | Activities of daily living impaired | FAERS: 1 | US FAERS | |
| 112 | Acute myocardial infarction | FAERS: 1 | US FAERS | |
| 113 | Administration site extravasation | FAERS: 1 | US FAERS | |
| 114 | Agitation | FAERS: 1 | US FAERS | |
| 115 | Agranulocytosis | FAERS: 1 | US FAERS | |
| 116 | Anxiety | FAERS: 1 | US FAERS | |
| 117 | Aspergillosis | FAERS: 1 | US FAERS | |
| 118 | Atherosclerosis | FAERS: 1 | US FAERS | |
| 119 | Basophilia | FAERS: 1 | US FAERS | |
| 120 | Biopsy bone marrow abnormal | FAERS: 1 | US FAERS | |
| 121 | Blood arsenic increased | FAERS: 1 | US FAERS | |
| 122 | Blood count abnormal | FAERS: 1 | US FAERS | |
| 123 | Blood potassium abnormal | FAERS: 1 | US FAERS | |
| 124 | Blood product transfusion dependent | FAERS: 1 | US FAERS | |
| 125 | Blood triglycerides increased | FAERS: 1 | US FAERS | |
| 126 | Blood urea increased | FAERS: 1 | US FAERS | |
| 127 | Bone Tuberculosis | FAERS: 1 | US FAERS | |
| 128 | Bone erosion | FAERS: 1 | US FAERS | |
| 129 | Bone lesion | FAERS: 1 | US FAERS | |
| 130 | Bronchopulmonary Aspergillosis | FAERS: 1 | US FAERS | |
| 131 | Capsule physical issue | FAERS: 1 | US FAERS | |
| 132 | Carcinoembryonic antigen increased | FAERS: 1 | US FAERS | |
| 133 | Cardiac Arrest | FAERS: 1 | US FAERS | |
| 134 | Cardiomegaly | FAERS: 1 | US FAERS | |
| 135 | Catheter related complication | FAERS: 1 | US FAERS | |
| 136 | Cell Death | FAERS: 1 | US FAERS | |
| 137 | Cellulitis | FAERS: 1 | US FAERS | |
| 138 | Cerebellar infarction | FAERS: 1 | US FAERS | |
| 139 | Cerebral Thrombosis | FAERS: 1 | US FAERS | |
| 140 | Clonus | FAERS: 1 | US FAERS | |
| 141 | Cognitive deterioration | FAERS: 1 | US FAERS | |
| 142 | Creatinine renal clearance increased | FAERS: 1 | US FAERS | |
| 143 | Deafness Neurosensory | FAERS: 1 | US FAERS | |
| 144 | Depressed Level of Consciousness | FAERS: 1 | US FAERS | |
| 145 | Diabetes Mellitus | FAERS: 1 | US FAERS | |
| 146 | Duodenal Ulcer | FAERS: 1 | US FAERS | |
| 147 | Dysarthria | FAERS: 1 | US FAERS | |
| 148 | Dysgeusia | FAERS: 1 | US FAERS | |
| 149 | Electroencephalogram abnormal | FAERS: 1 | US FAERS | |
| 150 | Electrolyte imbalance | FAERS: 1 | US FAERS | |
| 151 | Electromechanical dissociation | FAERS: 1 | US FAERS | |
| 152 | Enteritis | FAERS: 1 | US FAERS | |
| 153 | Enterocolitis | FAERS: 1 | US FAERS | |
| 154 | Epistaxis | FAERS: 1 | US FAERS | |
| 155 | Exposure via inhalation | FAERS: 1 | US FAERS | |
| 156 | Feeling abnormal | FAERS: 1 | US FAERS | |
| 157 | Fibrin D dimer increased | FAERS: 1 | US FAERS | |
| 158 | Gastrointestinal toxicity | FAERS: 1 | US FAERS | |
| 159 | Hemiparesis | FAERS: 1 | US FAERS | |
| 160 | Hepatic cancer metastatic | FAERS: 1 | US FAERS | |
| 161 | Hepatitis | FAERS: 1 | US FAERS | |
| 162 | Hyperpyrexia | FAERS: 1 | US FAERS | |
| 163 | Immunosuppression | FAERS: 1 | US FAERS | |
| 164 | Increased tendency to bruise | FAERS: 1 | US FAERS | |
| 165 | Induration | FAERS: 1 | US FAERS | |
| 166 | Infection in an immunocompromised host | FAERS: 1 | US FAERS | |
| 167 | Infusion site erythema | FAERS: 1 | US FAERS | |
| 168 | Infusion site reaction | FAERS: 1 | US FAERS | |
| 169 | Infusion site swelling | FAERS: 1 | US FAERS | |
| 170 | Injection site pain | FAERS: 1 | US FAERS | |
| 171 | Joint injury | FAERS: 1 | US FAERS | |
| 172 | Karnofsky scale worsened | FAERS: 1 | US FAERS | |
| 173 | Laboratory test interference | FAERS: 1 | US FAERS | |
| 174 | Lethargy | FAERS: 1 | US FAERS | |
| 175 | Leukostasis | FAERS: 1 | US FAERS | |
| 176 | Light chain analysis increased | FAERS: 1 | US FAERS | |
| 177 | Liver Abscess | FAERS: 1 | US FAERS | |
| 178 | Lung Injury | FAERS: 1 | US FAERS | |
| 179 | Lung infection pseudomonal | FAERS: 1 | US FAERS | |
| 180 | Lymphopenia | FAERS: 1 | US FAERS | |
| 181 | Malaise | FAERS: 1 | US FAERS | |
| 182 | Mental status changes | FAERS: 1 | US FAERS | |
| 183 | Mucormycosis | FAERS: 1 | US FAERS | |
| 184 | Myocarditis | FAERS: 1 | US FAERS | |
| 185 | Nasopharyngitis | FAERS: 1 | US FAERS | |
| 186 | Neck Pain | FAERS: 1 | US FAERS | |
| 187 | Nerve injury | FAERS: 1 | US FAERS | |
| 188 | Neuralgia | FAERS: 1 | US FAERS | |
| 189 | Neuroblastoma | FAERS: 1 | US FAERS | |
| 190 | Occupational exposure to product | FAERS: 1 | US FAERS | |
| 191 | Oropharyngeal discomfort | FAERS: 1 | US FAERS | |
| 192 | Oropharyngeal pain | FAERS: 1 | US FAERS | |
| 193 | Pain | FAERS: 1 | US FAERS | |
| 194 | Palpitations | FAERS: 1 | US FAERS | |
| 195 | Petechiae | FAERS: 1 | US FAERS | |
| 196 | Plasmapheresis | FAERS: 1 | US FAERS | |
| 197 | Polyneuropathy | FAERS: 1 | US FAERS | |
| 198 | Product container issue | FAERS: 1 | US FAERS | |
| 199 | Product storage error | FAERS: 1 | US FAERS | |
| 200 | Psoriasis | FAERS: 1 | US FAERS | |
| 201 | Renal tubular necrosis | FAERS: 1 | US FAERS | |
| 202 | Restless Legs Syndrome | FAERS: 1 | US FAERS | |
| 203 | Restlessness | FAERS: 1 | US FAERS | |
| 204 | Rhabdomyolysis | FAERS: 1 | US FAERS | |
| 205 | Shock | FAERS: 1 | US FAERS | |
| 206 | Sinus Tachycardia | FAERS: 1 | US FAERS | |
| 207 | Syncope | FAERS: 1 | US FAERS | |
| 208 | Therapy non-responder | FAERS: 1 | US FAERS | |
| 209 | Throat irritation | FAERS: 1 | US FAERS | |
| 210 | Thrombophlebitis | FAERS: 1 | US FAERS | |
| 211 | Tinnitus | FAERS: 1 | US FAERS | |
| 212 | Transplant | FAERS: 1 | US FAERS | |
| 213 | Tuberculosis | FAERS: 1 | US FAERS | |
| 214 | Urine arsenic increased | FAERS: 1 | US FAERS | |
| 215 | VIIth nerve paralysis | FAERS: 1 | US FAERS | |
| 216 | Venous occlusion | FAERS: 1 | US FAERS | |
| 217 | Weight decreased | FAERS: 1 | US FAERS | |
| 218 | Wheezing | FAERS: 1 | US FAERS |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.